U.S. Markets closed

Alexion Pharmaceuticals, Inc. (ALXN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
115.14-3.07 (-2.60%)
At close: 4:00PM EDT

115.14 0.00 (0.00%)
After hours: 4:15PM EDT

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard
Boston, MA 02210
United States
475 230 2596
http://www.alexion.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3,082

Key Executives

NameTitlePayExercisedYear Born
Dr. Ludwig N. HantsonCEO & Director3.7MN/A1963
Dr. Aradhana Sarin M.D.Exec. VP & CFO1.5MN/A1975
Mr. Brian M. GoffExec. VP and Chief Commercial & Global Operations Officer1.68MN/A1969
Dr. John J. OrloffExec. VP and Head of R&D1.76MN/A1957
Mr. Daniel A. Bazarko CPAChief Accounting Officer & Sr. VPN/AN/AN/A
Mr. Christopher J. Stevo CFAHead of Investor RelationsN/AN/AN/A
Ms. Indrani M. Lall FranchiniExec. VP & Chief Compliance OfficerN/AN/A1972
Ms. Ellen V. Chiniara J.D., Esq.Exec. VP, Gen. Counsel & Corp. Sec.N/AN/A1959
Megan GoulartSr. Director of Corp. CommunicationsN/AN/AN/A
Becky LillieInterim Chief Human Experience OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Corporate Governance

Alexion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 31, 2019 is 5. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.